$SYBX
SYNLOGIC, INC.

2017 Q2 Form 10-Q Financial Statement

#000152759917000012 Filed on May 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $2.111M $111.0K $111.0K
YoY Change 1801.8% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.040M $2.370M $2.130M
YoY Change 166.67% 11.27% 150.59%
% of Gross Profit
Research & Development $8.532M $5.118M $4.523M
YoY Change 131.72% 13.15% 32.95%
% of Gross Profit
Depreciation & Amortization $13.00K $5.000K $19.00K
YoY Change -50.0% -73.68% 90.0%
% of Gross Profit
Operating Expenses $11.57M $7.485M $3.937M
YoY Change 127.63% 90.12% -7.99%
Operating Profit -$9.457M -$7.374M -$3.826M
YoY Change 90.24% 92.73%
Interest Expense $7.000K $8.000K $80.00K
YoY Change -107.78% -90.0%
% of Operating Profit
Other Income/Expense, Net -$10.00K $6.000K $82.00K
YoY Change -110.75% -92.68%
Pretax Income -$9.390M -$7.370M -$6.570M
YoY Change 321.08% 12.18% 53.5%
Income Tax
% Of Pretax Income
Net Earnings -$9.388M -$7.368M -$3.828M
YoY Change 88.82% 92.48% -10.54%
Net Earnings / Revenue -444.72% -6637.84% -3448.65%
Basic Earnings Per Share
Diluted Earnings Per Share -$304.5K -$3.859M -$2.205M
COMMON SHARES
Basic Shares Outstanding 20.86M shares 20.86M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.70M $57.50M $80.60M
YoY Change -34.3% -28.66% 101.0%
Cash & Equivalents $15.22M $17.12M $52.88M
Short-Term Investments $32.50M $40.40M $27.70M
Other Short-Term Assets $400.0K $600.0K $900.0K
YoY Change -55.56% -33.33% 800.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $48.11M $58.15M $81.60M
YoY Change -34.55% -28.74% 101.98%
LONG-TERM ASSETS
Property, Plant & Equipment $13.00K $26.00K $500.0K
YoY Change -98.92% -94.8% 400.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $2.400M
YoY Change -100.0%
Total Long-Term Assets $13.00K $2.459M $500.0K
YoY Change -99.65% 391.8% 400.0%
TOTAL ASSETS
Total Short-Term Assets $48.11M $58.15M $81.60M
Total Long-Term Assets $13.00K $2.459M $500.0K
Total Assets $48.12M $60.61M $82.10M
YoY Change -37.67% -26.18% 102.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $47.00K $371.0K $1.200M
YoY Change -96.87% -69.08% 0.0%
Accrued Expenses $1.400M $4.500M $2.000M
YoY Change -36.36% 125.0% 81.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.422M $4.857M $3.200M
YoY Change -61.57% 51.78% 39.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.422M $4.857M $3.200M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.422M $4.857M $3.200M
YoY Change -61.57% 51.78% 39.13%
SHAREHOLDERS EQUITY
Retained Earnings -$17.00K -$17.00K
YoY Change
Common Stock $163.9M $163.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.70M $55.75M $78.90M
YoY Change
Total Liabilities & Shareholders Equity $48.12M $60.61M $82.10M
YoY Change -37.67% -26.18% 102.72%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$9.388M -$7.368M -$3.828M
YoY Change 88.82% 92.48% -10.54%
Depreciation, Depletion And Amortization $13.00K $5.000K $19.00K
YoY Change -50.0% -73.68% 90.0%
Cash From Operating Activities -$7.640M -$3.216M -$8.973M
YoY Change 48.93% -64.16% 97.21%
INVESTING ACTIVITIES
Capital Expenditures -$290.0K $125.0K $143.0K
YoY Change -29.27% -12.59% -1530.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$27.72M
YoY Change -100.0% -100.0%
Cash From Investing Activities -$290.0K $3.880M -$27.87M
YoY Change -98.29% -113.92% 278550.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.61M $25.00K $0.00
YoY Change 406000.0% -100.0%
NET CHANGE
Cash From Operating Activities -7.640M -$3.216M -$8.973M
Cash From Investing Activities -290.0K $3.880M -$27.87M
Cash From Financing Activities 40.61M $25.00K $0.00
Net Change In Cash 32.68M $689.0K -$36.84M
YoY Change -248.01% -101.87% -219.57%
FREE CASH FLOW
Cash From Operating Activities -$7.640M -$3.216M -$8.973M
Capital Expenditures -$290.0K $125.0K $143.0K
Free Cash Flow -$7.350M -$3.341M -$9.116M
YoY Change 55.72% -63.35% 100.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001527599
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20856693 shares
CY2017Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2017Q1 dei Entity Number Of Employees
EntityNumberOfEmployees
7 employee
CY2016Q3 dei Entity Number Of Employees
EntityNumberOfEmployees
36 employee
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
Mirna Therapeutics, Inc.
CY2016Q4 mirn Accrued Liabilities Employee Related Liabilities And Taxes Payable Current
AccruedLiabilitiesEmployeeRelatedLiabilitiesAndTaxesPayableCurrent
2400000 USD
CY2017Q1 mirn Accrued Liabilities Employee Related Liabilities And Taxes Payable Current
AccruedLiabilitiesEmployeeRelatedLiabilitiesAndTaxesPayableCurrent
4486000 USD
CY2017Q1 mirn Available For Sale Securities Continuous Unrealized Loss Position Amortized Cost
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAmortizedCost
40000000 USD
CY2017Q1 mirn Available For Sale Securities Debt Maturities After One Year
AvailableForSaleSecuritiesDebtMaturitiesAfterOneYear
0 USD
CY2017Q1 mirn Cash And Cash Equivalents And Available For Sale Securities
CashAndCashEquivalentsAndAvailableForSaleSecurities
57500000 USD
CY2016Q1 mirn Fair Value Asset Liability Transfers Between Level1 Level2 And Level3 Amount
FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount
0 USD
CY2017Q1 mirn Fair Value Asset Liability Transfers Between Level1 Level2 And Level3 Amount
FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount
0 USD
CY2010Q3 mirn Grant Awards Term
GrantAwardsTerm
P3Y
CY2016Q2 mirn Lessee Leasing Arrangements Operating Leases Areaof Leased Property
LesseeLeasingArrangementsOperatingLeasesAreaofLeasedProperty
23578 sqft
CY2017Q1 mirn Number Of Draws On Additional Improvement Allowance
NumberOfDrawsOnAdditionalImprovementAllowance
0 draw
CY2017Q1 mirn Number Of Terms Extend Lease
NumberOfTermsExtendLease
2 term
CY2017Q1 mirn Number Of Votes Per Common Stock
NumberOfVotesPerCommonStock
1 vote
CY2017Q1 mirn Operating Lease Percentage Increase In Base Rent Expense
OperatingLeasePercentageIncreaseInBaseRentExpense
0.03
CY2017Q1 mirn Operating Lease Rent Expense Base Yearly Rental
OperatingLeaseRentExpenseBaseYearlyRental
600000 USD
CY2017Q1 mirn Operating Leases Future Minimum Payments Due Year Five And Thereafter
OperatingLeasesFutureMinimumPaymentsDueYearFiveAndThereafter
4565888 USD
CY2010Q3 mirn Proceedsfrom Grant Awards
ProceedsfromGrantAwards
10300000 USD
CY2017Q1 mirn Rent Free Term
RentFreeTerm
P3M
CY2016Q1 mirn Severanceand Employee Retention Costs
SeveranceandEmployeeRetentionCosts
0 USD
CY2017Q1 mirn Severanceand Employee Retention Costs
SeveranceandEmployeeRetentionCosts
204000 USD
CY2017Q1 mirn Tenant Improvement Allowance
TenantImprovementAllowance
1900000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
361000 USD
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
371000 USD
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-19000 USD
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-87000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31000 USD
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-102791000 USD
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-107771000 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
163126000 USD
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
163518000 USD
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
447000 USD
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
364000 USD
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1915709 shares
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1611321 shares
CY2016Q4 us-gaap Assets
Assets
64166000 USD
CY2017Q1 us-gaap Assets
Assets
60608000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
61380000 USD
CY2017Q1 us-gaap Assets Current
AssetsCurrent
58149000 USD
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
44066000 USD
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
40408000 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000 USD
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8000 USD
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
17000 USD
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
44070000 USD
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
40425000 USD
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
17000 USD
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
44066000 USD
CY2017Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
40408000 USD
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
1053000 USD
CY2017Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
89713000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52875000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16432000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17121000 USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20841393 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20856693 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20841393 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20856693 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
21000 USD
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
21000 USD
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6562000 USD
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4990000 USD
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2448000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10000 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-247000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1524000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
192000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3216000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-6571000 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-36838000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
689000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27865000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3880000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8973000 USD
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0 USD
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2130000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2264000 USD
CY2016Q1 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2017Q1 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-262000 USD
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
82000 USD
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
86000 USD
CY2017Q1 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P60M
CY2017Q1 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P123M
CY2016Q4 us-gaap Liabilities
Liabilities
3814000 USD
CY2017Q1 us-gaap Liabilities
Liabilities
4857000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64166000 USD
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60608000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2761000 USD
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4857000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-4977000 USD
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6571000 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4977000 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
6653000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
5063000 USD
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6917376 USD
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
652340 USD
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
633364 USD
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
614855 USD
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
450929 USD
CY2016Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
9000 USD
CY2017Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-13000 USD
CY2016Q1 us-gaap Other Restructuring Costs
OtherRestructuringCosts
0 USD
CY2016 us-gaap Other Restructuring Costs
OtherRestructuringCosts
1500000 USD
CY2017Q1 us-gaap Other Restructuring Costs
OtherRestructuringCosts
2353000 USD
CY2017Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
1319000 USD
CY2016Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
27722000 USD
CY2017Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
12019000 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
143000 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
882000 USD
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
620000 USD
CY2016Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0 USD
CY2017Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
15577000 USD
CY2016Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2017Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
325000 USD
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
385000 USD
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
62000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
354000 USD
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26000 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4523000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
242000 USD
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2432000 USD
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2433000 USD
CY2016Q4 us-gaap Restructuring Charges
RestructuringCharges
4400000 USD
us-gaap Restructuring Charges
RestructuringCharges
7000000 USD
CY2017Q1 us-gaap Restructuring Charges
RestructuringCharges
2557000 USD
CY2016Q1 us-gaap Restructuring Costs
RestructuringCosts
0 USD
CY2017Q1 us-gaap Restructuring Costs
RestructuringCosts
2557000 USD
CY2016Q4 us-gaap Restructuring Reserve
RestructuringReserve
2662000 USD
CY2017Q1 us-gaap Restructuring Reserve
RestructuringReserve
3900000 USD
CY2017Q1 us-gaap Restructuring Reserve
RestructuringReserve
3900000 USD
CY2016Q1 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
0 USD
CY2017Q1 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
2557000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4000 USD
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
447000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
364000 USD
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
692798 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
278593 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.52
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1905214 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1611321 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.39
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.40
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.45
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.65
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M27D
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M13D
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15300 shares
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
60352000 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
55751000 USD
CY2016Q4 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
1400000 USD
CY2016 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
1400000 USD
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20830555 shares
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20850494 shares
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires the Company&#8217;s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Amounts included in the financial statements, such those recorded in restructuring charges, can result from a complex series of judgments about future events and uncertainties and can heavily rely on estimates and assumptions. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001527599-17-000012-index-headers.html Edgar Link pending
0001527599-17-000012-index.html Edgar Link pending
0001527599-17-000012.txt Edgar Link pending
0001527599-17-000012-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mirn-20170331.xml Edgar Link completed
mirn-20170331.xsd Edgar Link pending
mirn-20170331_cal.xml Edgar Link unprocessable
mirn-20170331_def.xml Edgar Link unprocessable
mirn-20170331_lab.xml Edgar Link unprocessable
mirn-20170331_pre.xml Edgar Link unprocessable
mirn_033117x10qdocument.htm Edgar Link pending
mirn_03312017x10qex311.htm Edgar Link pending
mirn_03312017x10qex312.htm Edgar Link pending
mirn_03312017x10qex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending